Berzosertib
- Generic Name
- Berzosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25N5O3S
- CAS Number
- 1232416-25-9
- Unique Ingredient Identifier
- L423PRV3V3
- Background
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
- Associated Conditions
- -
- Associated Therapies
- -
ATRi Transition Rollover Study
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1
- Registration Number
- NCT03309150
- Locations
- π¬π§
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Metastatic Ovarian CarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaStage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7Ovarian Endometrioid TumorRecurrent Primary Peritoneal CarcinomaMetastatic Primary Peritoneal CarcinomaRecurrent Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT02627443
- Locations
- πΊπΈ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈMayo Clinic in Florida, Jacksonville, Florida, United States
πΊπΈUniversity of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT02595892
- Locations
- πΊπΈ
UC San Diego Moores Cancer Center, La Jolla, California, United States
πΊπΈMayo Clinic in Florida, Jacksonville, Florida, United States
πΊπΈUniversity of Virginia Cancer Center, Charlottesville, Virginia, United States
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Metastatic Pancreatic CarcinomaRefractory Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC v8Refractory Colorectal CarcinomaMetastatic Lung Small Cell CarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Lung Cancer AJCC v8Unresectable Colorectal CarcinomaUnresectable Lung Small Cell Carcinoma
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT02595931
- Locations
- πΊπΈ
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈLos Angeles General Medical Center, Los Angeles, California, United States
πΊπΈStanford Cancer Institute Palo Alto, Palo Alto, California, United States
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT02589522
- Locations
- πΊπΈ
Mayo Clinic in Florida, Jacksonville, Florida, United States
πΊπΈUniversity of California Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈUniversity of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
- Conditions
- Head and Neck Carcinoma of Unknown PrimaryStage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT02567422
- Locations
- πΊπΈ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈUniversity of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 87
- Registration Number
- NCT02567409
- Locations
- πΊπΈ
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈUSC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈUniversity of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.